Kala Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Kala Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014089
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kala Pharmaceuticals Inc (Kala Pharmaceuticals) is a clinical stage pharmaceutical company which focuses on nanoparticle-based treatments for ocular diseases affecting both front and back of the eye. The company’s lead program MPP nanosuspension of an ophthalmic corticosteroid is under phase III clinical development for the treatment of post-surgical inflammation, ocular inflammation, meibomian gland disease and dry eye disease. Kala Pharmaceuticals is also developing a small molecule receptor tyrosine kinase inhibitor (RTKi) program for the treatment of wet age-related macular degeneration (AMD). The company is funded by life science investors such as Cam Capital, Longitude Capital Management, Lux Capital Management, RA Capital Management, Third Rock Ventures and others. Kala Pharmaceuticals is headquartered in Waltham, Massachusetts, the US.

Kala Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Kala Pharma Raises USD68 Million in Series C Financing Round 10
Kala Pharma Raises USD7 Million in Venture Financing 12
Kala Pharma Raises Us$22.5 Million In Series B Venture Financing 13
Kala Pharma Raises US$11.5 Million In Series A Financing 15
Kala Pharma Raises US$6.2 Million In Seed Financing 17
Equity Offering 18
Kala Pharma Raises USD103.5 Million in IPO 18
Kala Pharmaceuticals Inc – Key Competitors 20
Kala Pharmaceuticals Inc – Key Employees 21
Kala Pharmaceuticals Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Nov 07, 2017: Kala Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Business Update 23
Corporate Communications 25
Nov 13, 2017: Kala Pharmaceuticals Appoints Todd Bazemore as Chief Operating Officer 25
Oct 02, 2017: Kala Pharmaceuticals Appoints Andrew I. Koven to Board of Directors 26
Product Approvals 27
Oct 25, 2017: Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for INVELTYS (KPI-121 1%) 27
Clinical Trials 28
May 01, 2017: Kala Pharmaceuticals Announces Positive Results from Confirmatory Phase 3 Trial of KPI-121 1% Following Cataract Surgery 28
Jan 06, 2017: Kala Pharmaceuticals to Present Update on Phase 3 Programs at the 35th Annual J.P. Morgan Healthcare Conference 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Kala Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Kala Pharma Raises USD68 Million in Series C Financing Round 10
Kala Pharma Raises USD7 Million in Venture Financing 12
Kala Pharma Raises Us$22.5 Million In Series B Venture Financing 13
Kala Pharma Raises US$11.5 Million In Series A Financing 15
Kala Pharma Raises US$6.2 Million In Seed Financing 17
Kala Pharma Raises USD103.5 Million in IPO 18
Kala Pharmaceuticals Inc, Key Competitors 20
Kala Pharmaceuticals Inc, Key Employees 21

★海外企業調査レポート[Kala Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Samsung Electro-Mechanics Co Ltd (009150):企業の財務・戦略的SWOT分析
    Samsung Electro-Mechanics Co Ltd (009150) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Keysight Technologies Inc:戦略・SWOT・企業財務分析
    Keysight Technologies Inc - Strategy, SWOT and Corporate Finance Report Summary Keysight Technologies Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Albireo Pharma Inc (ALBO):企業の財務・戦略的SWOT分析
    Albireo Pharma Inc (ALBO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Evonik Industries AG:企業の戦略・SWOT・財務情報
    Evonik Industries AG - Strategy, SWOT and Corporate Finance Report Summary Evonik Industries AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Bank Of Ningbo Co. Ltd.
    Bank Of Ningbo Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Bank Of Ningbo Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Gazprom (GAZP):石油・ガス:M&Aディール及び事業提携情報
    Summary Gazprom is an integrated global oil and gas company. It carries out the exploration, production, transportation, storage, processing and marketing of natural gas, gas condensate and crude oil. The company also sells gas as a vehicle fuel and participates in the generation and marketing of he …
  • Informa PLC (INF):企業の財務・戦略的SWOT分析
    Informa PLC (INF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Cisco Systems, Inc.:企業の戦略・SWOT・財務情報
    Cisco Systems, Inc. - Strategy, SWOT and Corporate Finance Report Summary Cisco Systems, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Goldin Properties Holdings Ltd:企業の戦略・SWOT・財務分析
    Goldin Properties Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Goldin Properties Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Aarti Drugs Ltd (AARTIDRUGS):企業の財務・戦略的SWOT分析
    Summary Aarti Drugs Ltd (ADL), is a contract manufacturer of pharmaceutical products that offers therapeutic products, ingredients, bulk drugs, and chemicals. The company's products include active pharmaceutical ingredients, pharma intermediates, and specialty chemicals. Its active pharmaceutical in …
  • Landis+Gyr AG:企業の戦略的SWOT分析
    Landis+Gyr AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • MiMedx Group Inc (MDXG):企業の財務・戦略的SWOT分析
    Summary MiMedx Group Inc (MiMedx) is a biopharmaceutical company that develops, manufactures and markets regenerative biologics utilizing human placental allografts. The company provides products such as amniotic membrane, umbilical cord, placental ECM and amniotic fluid. It utilizes proprietary pur …
  • Intarcia Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Intarcia Therapeutics Inc (Intarcia), formerly BioMedicines Inc, is a biopharmaceutical company that discovers, develops and commercializes drug therapies and reduces effects for chronic diseases. The company’s product candidate include ITCA 650 is in Phase III clinical trial. Its ITCA 650 i …
  • Martindale Pharmaceuticals Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Martindale Pharmaceuticals Ltd (Martindale), a subsidiary of Cardinal Health Inc is a pharmaceutical company that offers formulations. The company provides hospital-initiated medicines in emergency medicine and differentiated products in complex neurological conditions,opioid addiction and p …
  • Cortec GmbH:製品パイプライン分析
    Summary Cortec GmbH (Cortec), a subsidiary of Iron Force Industrial Co Ltd is a medical device company that develops neurons technology platform for the measurement and stimulation of brain activity. The company provides products for clinical use and scientific research. It is developing implants th …
  • InnaVirVax SA-製薬・医療分野:企業M&A・提携分析
    Summary InnaVirVax SA (InnaVirVax) is a biopharmaceutical company which discovers and develops products for the treatment of HIV/AIDS infection pathologically and novel cancer therapies. The company's pipeline product portfolio comprise DIAG-3S, an AIDS prognostic test; VAC-3S, an HIV AIDs therapeut …
  • Alberici Corp:企業の戦略的SWOT分析
    Alberici Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Altin Yunus Cesme Turistik Tesisler A.S.:企業の戦略・SWOT・財務情報
    Altin Yunus Cesme Turistik Tesisler A.S. - Strategy, SWOT and Corporate Finance Report Summary Altin Yunus Cesme Turistik Tesisler A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Yanmar Co Ltd:企業の戦略的SWOT分析
    Yanmar Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Deutsche Borse Ag:企業の戦略・SWOT・財務分析
    Deutsche Borse Ag - Strategy, SWOT and Corporate Finance Report Summary Deutsche Borse Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆